A small Irish-based laboratory that conducts live trials testing potential Covid-19 and other vaccines for the British government is the biggest winner on the Irish stock exchange this year, with the stock gaining 352% during the pandemic.
That performance puts it up there among the best stock performances across Europe, beating in percentage terms even the gains posted by Germany’s BionNTech, led by Professor Ugur Salin, who has helped produce one of the two potentially most successful vaccines.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).
